Fluctuating Values of Molecular Residual Disease (MRD) without Molecular Progression After Imatinib Discontinuation in Patients (pts) with Chronic Myeloid Leukemia (CML) Who Have Maintained Complete Molecular Response: Implications for Re-Treatment Criteria and Role of Prior Interferon Therapy. A Pilot Study of the French CML Group (FILMC),
| Autor: | Rousselot, Philippe *, Makhoul, Pascale Cony *, Rea, Delphine *, Agape, Philippe *, Nicolini, Franck E, Legros, Laurence *, Tulliez, Michel *, Roy, Lydia *, Charbonnier, Aude *, Guilhot, Joelle *, Guilhot, Francois, Mahon, Francois-Xavier |
|---|---|
| Zdroj: | In Blood 18 November 2011 118(21):3781-3781 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|